Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Peripheral NeuropathyMultiple Myeloma, Neoplasms
Interventions
DRUG

Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet

"Bortezomib (VELCADE® 3.5mg/ml) is diluted by 1.4 ml of normal saline (0.9%) solution to give a solution of a concentration of 2.5 mg/mL then the dose will be 1.3 mg/m2 administered subcutaneously at thigh or abdomen at days 1,8,15,22.~Lenalidomide is given as 25mg orally at days from 1 to 21. Dexamethasone is given as 40mg orally at days 1,8,15,22. Fenofibrate 160 mg tablets orally once daily during the period of the 6 cycles of the(VRd) regimen."

DRUG

Bortezomib + Lenalidomide + Dexamethasone

"Bortezomib (VELCADE® 3.5mg/ml) is diluted by 1.4 ml of normal saline (0.9%) solution to give a solution of a concentration of 2.5 mg/mL then the dose will be 1.3 mg/m2 administered subcutaneously at thigh or abdomen at days 1,8,15,22.~Lenalidomide is given as 25mg orally at days from 1 to 21. Dexamethasone is given as 40mg orally at days 1,8,15,22."

Trial Locations (2)

Unknown

Damanhur Oncology Center, Damanhur

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER